Prostaglandin E1 at clinically relevant concentrations inhibits aggregation of platelets under synergic interaction with endothelial cells

• Published in: Acta anaesthesiologica Scandinavica Vol. 46; no. 8; pp. 987 - 993
• Main Authors: Koga, T., Az-Ma, T., Yuge, O.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Munksgaard International Publishers 01.09.2002; Blackwell
• Subjects: Alprostadil - pharmacology; Animals; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Endothelial cells; Endothelium, Vascular - drug effects; Endothelium, Vascular - metabolism; Epoprostenol - pharmacology; Medical sciences; NG-Nitroarginine Methyl Ester - pharmacology; nitric oxide; Nitric Oxide - pharmacology; Nitric Oxide Synthase - antagonists & inhibitors; Pharmacology. Drug treatments; platelet aggregation; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; prostacyclin; prostaglandin E1; Swine; synergic effect; Human; Cell culture; Endothelial cell; Prostaglandin I2; Prostaglandin E1; In vitro; Synergism; Antiplatelet agent; Pig; Aggregation; Vertebrata; Platelet; Mammalia; Animal; Nitric oxide; Artiodactyla; Ungulata

Background: The inhibitory effect of prostaglandin E1 (PGE1) on platelet aggregation is considered an important characteristic of this agent. However, the concentration of PGE1 to inhibit aggregation in vitro is higher than those of clinical use (1 ng/ml). To clarify whether PGE1 at clinically relev...